Orphan status for BCY's dextran-1 in cystic fibrosis.

[Guest guest]

Pharma Marketletter

                                 April 7, 2003

HEADLINE: Orphan status for BCY's dextran-1 in cystic fibrosis.

    BCY LifeSciences has been granted orphan-drug status in the USA for

dextran-1, the major constituent of BCY's lead compound, DCF 987, in the

treatment of cystic fibrosis. The drug is currently in a Phase II study

and is

due to report preliminary results this summer. Dextran-1 has the

potential to

thin mucus and reduce bacterial load in CF patients, according to Lorne

Meikle,

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/